AVBP
ArriVent BioPharma, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.33B
P/E Ratio
—
EPS
$-4.32
Beta
0.86
52W High
$32.14
52W Low
$16.10
50-Day MA
$25.18
200-Day MA
$21.67
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma, Inc. (AVBP) is a biopharmaceutical innovator focused on delivering groundbreaking therapies to address critical unmet medical needs in oncology and autoimmune disorders. The company boasts a robust pipeline of therapies, employing proprietary technologies backed by a strong scientific framework, which are designed to enhance patient outcomes considerably. By concentrating on high-growth sectors within the biopharma landscape, ArriVent positions itself as an attractive investment opportunity for institutional investors looking to engage in transformative healthcare solutions that hold the promise of significant market impact.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -58.90% |
| Return on Assets | -36.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.24 |
| Price-to-Book | 4.32 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $44.20M |
| Float | $27.72M |
| % Insiders | 2.92% |
| % Institutions | 96.68% |
Historical Volatility
HV 10-Day
44.73%
HV 20-Day
60.28%
HV 30-Day
59.27%
HV 60-Day
55.54%
HV Rank
76.2%
Volatility is currently contracting
Analyst Ratings
Consensus ($42.10 target)
12
BuyData last updated: 4/29/2026